- Open Access
Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein
BMC Neurosciencevolume 9, Article number: S9 (2008)
Protein kinases of the MARK family phosphorylate tau protein in its repeat domain and thereby regulate its affinity for microtubules and affect the aggregation of tau into Alzheimer paired helical filaments. We are searching for low molecular weight compounds to interfere with the activity of MARK and its pathways. Here we summarize structural features of MARK and cellular pathways of regulation.
Kinases of the MARK (microtubule-associated protein (MAP)-microtubule affinity regulating kinase)/Par-1 family play important roles in several contexts relevant for Alzheimer's disease (AD) research. The best-known property is that these kinases phosphorylate the tau protein in its repeat domain. The consequence is that tau looses its affinity for microtubules and detaches from them. The microtubules become destabilized, and the unbound tau is free to undergo abnormal aggregation. This process represents one of the hallmarks of AD. Furthermore, the sites on tau phosphorylated by MARK (KXGS motifs in the repeat domain) appear early in AD , MARK protein is elevated in neurofibrillary tangles in AD brain , and MARK phosphorylation sites on tau are elevated early in transgenic mouse models of tauopathy [3, 4].
Apart from neurodegeneration, MARK and its homologues belong to a set of conserved proteins that are essential for establishing cellular polarity, which is crucial for the development of an organism. Because of this property, these proteins were initially named Par (for 'partition-defective'), since mutations in the gene products lead to defects in the partitioning of the Caenorhabditis elegans zygote . The combination of Par genes has since been discovered and studied in many contexts, notably in polarity development in the fruit fly  and in the establishment of polarized epithelial cells . Besides tau, a number of other MARK target proteins have been identified. They include the MAPs related to tau (for example, MAP2, MAP4 and their isoforms) , other MAPs (for example, doublecortin), or proteins involved in phosphorylation signaling and 14-3-3 binding (for example, Cdc25, PTPH1, and KSR1) . In particular, the Par genes are involved in neuronal differentiation , and the activity of MARK2/Par-1 is necessary for the outgrowth of cell processes, neurites, and dendritic spines [11–13].
Our search for MARK was prompted by the observation of the phoshorylated KXGS motifs in tau protein and their strong effect on microtubule affinity. The kinase was identified and cloned on the basis of this property [14, 15]. The kinase subfamily contains four members, termed MARK1–4, encoded on chromosomes 1, 11, 14, and 19 in the human genome. MARK belongs to the AMPK (adenosine-monophosphate activated protein kinase) branch of the CAMK (calcium/calmodulin-dependent protein kinase) group of kinases . The kinase is relatively large (nearly 800 residues), contains several domains, and appears to be regulated by multiple pathways. Two of these were already anticipated when the kinase was originally isolated because two residues in the so-called 'activation loop' of the catalytic domain were phosphorylated. Subsequent work showed that phosphorylation of the first site (T208 in the MARK2 sequence) activated the kinase, whereas the second site was inhibitory (S212). Activation by phosphorylation at T208 can be achieved by the upstream kinase MARKK/TAO-1 , or alternatively by the kinase LKB1 . Inactivation by phosphorylation at S212 is achieved by the glycogene synthase kinase 3β (GSK3β) . Because of the relationship to tau phosphorylation in neurofibrillary pathology, we are interested in low molecular weight compounds by which the activity of MARK can be modulated. One example is that of hymenialdisine, which inhibits MARK and other kinases by binding in the catalytic pocket [12, 20]. Here we summarize some structural features of MARK and mechanisms of regulation that may serve as entry points for pharmacological intervention.
The major domains of MARK (Figure 1A) include an amino-terminal header, the kinase catalytic domain, the ubiquitin-associated (UBA) domain, a spacer domain, and the carboxy-terminal tail domain (containing the 'kinase-associated domain' (KA1)). All four MARK isoforms have a similar domain composition. UBA domains can be found by sequence homology in several other AMPK-related kinases, such as the salt-induced kinases SIK1–3 (also termed SIK, QIK and QSK) and the brain-selective kinases BRSK1/2 (also termed SAD kinase) . Predictions based on structure suggest 3-helix bundles resembling the UBA domain at analogous positions for several further kinases of the AMPK family, such as NUAK1/ARK5 (AMPK-related kinase 5; but not NUAK2/SNARK (sucrose non-fermenting 1 (SNF1)/AMPK-related kinase)), AMPKα1/2, MELK (maternal embryonic leucine zipper kinase), NIM1 (non-inducible immunity 1), SNRK (SNF1-related kinase), and HUNK (hormonally upregulated Neu-associated kinase) (Figure 1B).
The carboxy-terminal KA1 domains are only predicted for a subset of the AMPK family kinases, MARK1–4, AMPKα1/2, BRSK1/2 (alias SADK-A/B) and MELK (Figure 1B). Among the domains of MARK, three have been solved structurally at high resolution: the catalytic domain together with the UBA domain (by X-ray diffraction) [22–24]; and the tail domain (by NMR spectroscopy) . If not stated otherwise, residue numbers refer to MARK2 [UniProt: Q7KZI7], which is the isoform that has been resolved at the highest resolution so far [PDB: 2Y8G].
The catalytic domain (Figure 2A) has a bi-lobal structure typical of protein kinases, with a conserved active site cleft between the two lobes. The smaller amino-terminal lobe (approximately 80 residues) consists mainly of β-strands (β1 to β5) and a single, prominent α-helix (helix C), and the larger carboxy-terminal lobe (approximately 170 residues) is mostly α-helical. Both lobes contribute structural elements to the active site that are essential for the catalytic activity: the P-loop (phosphate-binding loop, also known as glycine-rich loop, G-loop), the catalytic loop, and the activation loop (also called T-loop). The P-loop, at the tip of the β1–β2 hairpin (GKGNFA in all MARK isoforms, residues 60–65 in MARK2), is rather flexible in the apo-state. In the active complex it locks in to the nucleotide and helps to position the γ-phosphate of the nucleotide for transfer to the substrate's phosphorylation site (by analogy to known structures of active protein kinase complexes). The catalytic loop (residues 171–183), part of the C-lobe, is located at the other side of the catalytic cleft, opposite to helix C and the P-loop. The catalytic loop contains an RD motif consisting of a highly conserved, catalytically active aspartate (D175), which is preceded by an arginine residue. In RD kinases that are regulated by T-loop phosphorylation, this arginine is assumed to interact with the primary phosphorylation site of the T-loop .
The T-loop is anchored to the base of the active site cleft via the Mg2+ binding loop starting with the DFG motif (residues 193–195). In inactive MARK, the T-loop is partially disordered and assumes a variety of conformations. It is folded over the cleft in the inactive state (Figure 2A) so that the access of the substrate peptide and ATP are blocked. As with many other RD kinases, activation of MARK can be achieved by phosphorylating the T-loop (at T208). By analogy with the structure of other kinases in the active state, phosphorylation of this residue likely triggers reorientation and stabilization of the T-loop leading to an 'active' conformation that allows binding of the substrate molecule (Figure 3).
The catalytic domain has a carboxy-terminal extension that starts with a highly charged four residue motif (ExxE, x = E or D, except for MARK4, EGEE) that resembles the common docking (CD) site in MAP kinases  and may represent an attachment of upstream or downstream regulatory cofactors. This motif is followed by an extended chain of amino acid residues that ends with the UBA domain, a small, globular domain that binds close to the amino terminus of the catalytic domain. The generic UBA domain consists of three short helices (α1–3) folded in a characteristic helical bundle. In all MARK crystals that have been solved so far, including constructs from MARK isoforms 1, 2, and 3, the UBA domain is unusually folded: helix α3 is inverted compared to the typical fold (Figure 2B).
Mechanisms of MARK regulation
As described above, MARK/Par-1 kinases can be activated by phosphorylation of a conserved threonine in the activation loop, T208 in MARK2 (Figure 4). Two upstream activating kinases have been identified, MARKK/TAO-1  and LKB1 . MARK2 purified from brain is, at least partially, also found to be phosphorylated at a second site, S212, adjacent to T208 . This particular serine can be phosphorylated by GSK3β and, as a result, MARK becomes inactive. The inhibitory phosphorylation by GSK3β even overrides previous activation by MARKK or LKB1 at T208 . These findings confirm earlier data, where site-directed mutagenesis of this residue to a phosphoserine-mimicking glutamate suggested that phosphorylation might be inhibitory . X-ray analysis of the catalytic domains of MARK1 and MARK2 confirm the important function of this particular serine in stabilizing the activation loop [23, 24]. This is illustrated in the structural model of MARK2 (Figure 3). In the inactive state of the kinase, the activation loop folds deep into the catalytic cleft, blocking the entry of the ATP and the substrate peptide (tau). Upon activation, the activation loop folds out of the catalytic cleft and resides between helix C and helix F, opening the cleft for ATP and the substrate. In this conformation, the S212 forms hydrogen bonds to the catalytic aspartate (D175) and a nearby lysine (K177), as proposed for PKA (PKA residues are T201, D166, and K168) . This interaction, together with the contacts of the phosphorylated T208 to helix C, fixes the activation loop in the open conformation that is crucial for activity. Mutation of S212 to either alanine or glutamate disrupts this stabilizing interaction, and the same is achieved when S212 is phosphorylated. Since the activation loops of the four MARK isoforms are nearly identical in sequence, these results are likely to hold for all.
The activity of MARK is additionally regulated by several mechanisms that all lead to reduced activity (Figure 4) . First, the activity is modulated by interaction with other proteins. Using a yeast two-hybrid screen, we identified the Ste20-kinase PAK5, which can bind to the catalytic domain of MARK, resulting in inhibition . Furthermore, MARK can also interact with the scaffold protein 14-3-3/Par-5 (one of the conserved polarity genes). Two different modes have been proposed for this interaction: 14-3-3 can bind in a phosphorylation-independent manner to a fragment containing the catalytic domain and the linker to the UBA domain of MARK/Par-1 . Alternatively, 14-3-3 can bind to the spacer domain after phosphorylation by atypical protein kinase C [32, 33]. These interactions not only regulate MARK spatially by altering its localization, but also inhibit the catalytic activity of the enzyme, probably by stabilizing the inhibitory interaction of the tail domain with the amino-terminal header or the catalytic domain (, and our unpublished data). The structural analysis of MARK  suggests further regulatory interactions with yet unknown proteins and the UBA domain – for example, poly-ubiquitin – leading to intracellular signaling. Finally, the CD site is known in MAP kinases for multiple interactions with upstream and downstream effectors ; this motif can be found in all MARK isoforms .
adenosine monophosphate-activated protein kinase
brain-selective kinase 1/2
glycogene synthase kinase 3β
MAP-microtubule affinity regulating kinase
maternal embryonic leucine zipper kinase
sucrose non-fermenting 1
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103: 26-35. 10.1007/s004010100423.
Chin JY, Knowles RB, Schneider A, Drewes G, Mandelkow EM, Hyman BT: Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol. 2000, 59: 966-971.
Mocanu M, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schönig K, Bujard H, Mandelkow E, et al: The potential for beta structure in the repeat domain of Tau protein determines aggregation, synaptic decay, neuronal loss, and co-assembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008,
Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schonig K, Bujard H, Haemisch A, Mandelkow E, et al: The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem. 2007, 282: 31755-31765. 10.1074/jbc.M705282200.
Kemphues K: PARsing embryonic polarity. Cell. 2000, 101: 345-348. 10.1016/S0092-8674(00)80844-2.
Shulman JM, Benton R, St Johnston D: The Drosophila homolog of C. elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole. Cell. 2000, 101: 377-388. 10.1016/S0092-8674(00)80848-X.
Cohen D, Brennwald PJ, Rodriguez-Boulan E, Musch A: Mammalian PAR-1 determines epithelial lumen polarity by organizing the microtubule cytoskeleton. J Cell Biol. 2004, 164: 717-727. 10.1083/jcb.200308104.
Ebneth A, Drewes G, Mandelkow EM, Mandelkow E: Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motil Cytoskeleton. 1999, 44: 209-224. 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4.
Drewes G: MARKing tau for tangles and toxicity. Trends Biochem Sci. 2004, 29: 548-555. 10.1016/j.tibs.2004.08.001.
Chen YM, Wang QJ, Hu HS, Yu PC, Zhu J, Drewes G, Piwnica-Worms H, Luo ZG: Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity. Proc Natl Acad Sci USA. 2006, 103: 8534-8539. 10.1073/pnas.0509955103.
Biernat J, Mandelkow EM: The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell. 1999, 10: 727-740.
Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, Mandelkow EM: Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell. 2002, 13: 4013-4028. 10.1091/mbc.02-03-0046.
Thies E, Mandelkow EM: Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007, 27: 2896-2907. 10.1523/JNEUROSCI.4674-06.2007.
Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt-Ulms G, Meyer HE, Mandelkow EM, Mandelkow E: Microtubule-associated protein/microtubule affinity-regulating kinase (p110 mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem. 1995, 270: 7679-7688. 10.1074/jbc.270.13.7679.
Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E: MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997, 89: 297-308. 10.1016/S0092-8674(00)80208-1.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science. 2002, 298: 1912-1934. 10.1126/science.1075762. Human Kinome provided courtesy of Cell Signaling Technology, inc. http://www.cellsignal.com
Timm T, Li XY, Biernat J, Jiao J, Mandelkow E, Vandekerckhove J, Mandelkow EM: MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J. 2003, 22: 5090-5101. 10.1093/emboj/cdg447.
Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, et al: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23: 833-843. 10.1038/sj.emboj.7600110.
Timm T, Balusamy K, Li X, Biernat J, Mandelkow E, Mandelkow EM: Glycogen synthase kinase (GSK) 3-beta directly phosphorylates serine 212 in the regulatory loop and inhibits microtubule affinity regulating kinase (MARK) 2. J Biol Chem. 2008, 283: 18873-18882. 10.1074/jbc.M706596200.
Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, et al: Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol. 2000, 7: 51-63. 10.1016/S1074-5521(00)00063-6.
Kishi M, Pan YA, Crump JG, Sanes JR: Mammalian SAD kinases are required for neuronal polarization. Science. 2005, 307: 929-932. 10.1126/science.1107403.
Murphy JM, Korzhnev DM, Ceccarelli DF, Briant DJ, Zarrine-Afsar A, Sicheri F, Kay LE, Pawson T: Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition and promotes interaction with the adjacent kinase domain. Proc Natl Acad Sci USA. 2007, 104: 14336-14341. 10.1073/pnas.0703012104.
Marx A, Nugoor C, Muller J, Panneerselvam S, Timm T, Bilang M, Mylonas E, Svergun DI, Mandelkow EM, Mandelkow E: Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2. J Biol Chem. 2006, 281: 27586-27599. 10.1074/jbc.M604865200.
Panneerselvam S, Marx A, Mandelkow EM, Mandelkow E: Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. Structure. 2006, 14: 173-183. 10.1016/j.str.2005.09.022.
Tochio N, Koshiba S, Kobayashi N, Inoue M, Yabuki T, Aoki M, Seki E, Matsuda T, Tomo Y, Motoda Y, et al: Solution structure of the kinase-associated domain 1 of mouse microtubule-associated protein/microtubule affinity-regulating kinase 3. Protein Sci. 2006, 15: 2534-2543. 10.1110/ps.062391106.
Johnson LN, Noble ME, Owen DJ: Active and inactive protein kinases: structural basis for regulation. Cell. 1996, 85: 149-158. 10.1016/S0092-8674(00)81092-2.
Tanoue T, Nishida E: Molecular recognitions in the MAP kinase cascades. Cell Signal. 2003, 15: 455-462. 10.1016/S0898-6568(02)00112-2.
Madhusudan , Trafny EA, Xuong NH, Adams JA, Ten Eyck LF, Taylor SS, Sowadski JM: cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer. Protein Sci. 1994, 3: 176-187.
Timm T, Matenia D, Li XY, Griesshaber B, Mandelkow EM: Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis. 2006, 3: 207-217. 10.1159/000095258.
Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J, Mandelkow E, Mandelkow EM: PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell. 2005, 16: 4410-4422. 10.1091/mbc.E05-01-0081.
Benton R, Palacios IM, St Johnston D: Drosophila 14-3-3/PAR-5 is an essential mediator of PAR-1 function in axis formation. Dev Cell. 2002, 3: 659-671. 10.1016/S1534-5807(02)00320-9.
Hurov JB, Watkins JL, Piwnica-Worms H: Atypical PKC phosphorylates PAR-1 kinases to regulate localization and activity. Curr Biol. 2004, 14: 736-741. 10.1016/j.cub.2004.04.007.
Suzuki A, Hirata M, Kamimura K, Maniwa R, Yamanaka T, Mizuno K, Kishikawa M, Hirose H, Amano Y, Izumi N, et al: aPKC acts upstream of PAR-1b in both the establishment and maintenance of mammalian epithelial polarity. Curr Biol. 2004, 14: 1425-1435. 10.1016/j.cub.2004.08.021.
Elbert M, Rossi G, Brennwald P: The yeast par-1 homologs kin1 and kin2 show genetic and physical interactions with components of the exocytic machinery. Mol Biol Cell. 2005, 16: 532-549. 10.1091/mbc.E04-07-0549.
Mueller TD, Feigon J: Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol. 2002, 319: 1243-1255. 10.1016/S0022-2836(02)00302-9.
DeLano WL: The PyMOL Molecular Graphics System (2002). [http://www.pymol.org]
This work was supported by the Max-Planck-Gesellschaft (MPG), the Deutsche Forschungsgemeinschaft and the Alzheimer Drug Discovery Foundation (ADDF, New York).
This article has been published as part of BMC Neuroscience Volume 9 Supplement 2: 2008 Proceedings of the 8th International Conference on Alzheimer's Disease Drug Discovery The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2202/9?issue=S2.
The authors declare that they have no competing interests.